FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approved a supplemental application for Singulair (montelukast) by Organon LLC, resulting in an update to the product labeling via a supplemental approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Exercise-induced Bronchoconstriction

Drugs mentioned

• SINGULAIR (montelukast)

Snippet

SUPPL AP for SINGULAIR (MONTELUKAST SODIUM)